New Scientific Advisors Focused on Cell Therapy in Immuno-Oncology and Autoimmunity Join Intellia Therapeutics

CAMBRIDGE, Mass., May 14, 2018 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, announced new scientific advisors in immuno-oncology and autoimmunity. The advisors hail from prestigious international institutions and collectively have both scientific and clinical expertise in cell therapies in these areas.